SR9243: an LXR inverse agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
SR9243 : A sulfonamide resulting from the formal condensation of the sulfonic acid group of mesitylene-2-sulphonic acid with the amino group of 2-(m-bromophenyl)ethylamine in which the nitrogen is substituted by a 4-[m-(methylsulfonyl)phenyl]benzyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 76073169 |
| CHEBI ID | 90842 |
| SCHEMBL ID | 15773799 |
| MeSH ID | M000610779 |
| Synonym |
|---|
| S7934 |
| CS-4514 |
| CHEBI:90842 |
| n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-n-{[3'-(methylsulfonyl)biphenyl-4-yl]methyl}benzenesulfonamide |
| sr-9243 |
| sr 9243 |
| SCHEMBL15773799 |
| sr9243 |
| 1613028-81-1 |
| AC-29034 |
| HY-16972 |
| 5-cyano-2'-{4-[2-(3-methyl-1h-indol-1-yl)ethyl]-1-piperazinyl}-n-[3-(1-pyrrolidinyl)propyl]-3-biphenylcarboximidic acid |
| J-690219 |
| AKOS026750218 |
| EX-A622 |
| n-(3-bromophenethyl)-2,4,6-trimethyl-n-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)benzenesulfonamide |
| n-[2-(3-bromophenyl)ethyl]-n-{[4-(3-methanesulfonylphenyl)phenyl]methyl}-2,4,6-trimethylbenzene-1-sulfonamide |
| sr9243, >=98% (hplc) |
| n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-n-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]benzenesulfonamide |
| mfcd29049514 |
| n-(3-bromophenethyl)-2,4,6-trimethyl-n-((3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide |
| FT-0700227 |
| BCP15765 |
| n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyln-{[3'-(methylsulfonyl)-4-biphenylyl]methyl} benzenesulfonamide |
| sr 9243;sr9243 |
| Q27162823 |
| AS-16933 |
| SB19147 |
| NCGC00389085-05 |
| n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-n-[[4-(3-methylsulfonylphenyl)phenyl]methyl]benzenesulfonamide |
| nsc787081 |
| nsc-787081 |
| nsc810522 |
| nsc-810522 |
| A883123 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with SR9243 significantly reduced the severity of hepatic inflammation and ameliorated hepatic fibrosis; simultaneously, body weight, serum glucose, and plasma lipid levels were controlled effectively." | ( Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. Chang, S; Huang, FZ; Huang, P; Jiang, XL; Kaluba, B; Mao, LF; Tang, XF; Zhang, ZP, 2018) | 1.1 |
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
| liver X receptor inverse agonist | An inverse agonist that binds to the same receptor as a liver X receptor agonist, but which induces a pharmacological response opposite to that agonist. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| sulfone | An organosulfur compound having the structure RS(=O)2R (R =/= H). |
| bromobenzenes | A member of the class of benzenes that is benzene substituted by at least one bromo group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||